Literature DB >> 213397

Coronaviridae: second report.

D A Tyrrell, D J Alexander, J D Almeida, C H Cunningham, B C Easterday, D J Garwes, J C Hierholzer, A Kapikian, M R Macnaughton, K McIntosh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 213397      PMCID: PMC7182642          DOI: 10.1159/000148996

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


× No keyword cloud information.
Further experience has confirmed our earlier recommendation that coronaviruses appear to form a quite closely related group. Firm evidence on the nucleic acids of several indicates that they have a single, large molecular weight, single-stranded RNA genome which carries a covalently attached poly(A) sequence at the 3′-terminus. Consistent with this result, the early reports of the presence of a viral particle polymerase have not been confirmed. The viruses are presumably positively stranded; the genomic RNA has been shown to be infectious, although it has not as yet been shown to code for viral polypeptides in a cell-free system. The position with the viral polypeptides is confusing; different numbers and molecular weights are found when the same viruses are studied in different laboratories and when different viruses are studied in the same laboratories. High and low molecular weight polypeptides can apparently be produced during extraction and separation. However, the internal polypeptide associated with the RNA seems to be of molecular weight about 50,000 in all cases which have been adequately studied. The lipids of only one virus have been examined. More work is needed on the polypeptides and their antigenic and biochemical characteristics. New viruses, which seem to have typical coronavirus morphology, have been recognized and tentatively added to the group, but further information is needed about their structure. There is still not enough evidence to justify subdividing the group. References included in the review by McIntosh [1] and in the report by Tyrrell et al. [2] are not repeated in this report. 1 Taxonomy 1.1 Family: Coronaviridae 1.3 Taxonomic status: Family with one genus Coronavirus. 2 The virion 2.1 Chemical composition 2.1.1 Nucleic acid 2.1.1.1 RNA 2.1.1.2 Single-stranded: HCV2 (229E) [3]; HCV (OC43) [4]; HEV [5]; IBV [6, 7, 8, 9]; TGEV [5]. 2.1.1.4 Number of pieces: One or several [3, 4, 5, 6, 7, 8, 9]. 2.1.1.5 Sedimentation coefficients: HCV (229E), 52S [3]; HCV (OC43), 70S [4]; HEV, 60-70S [5]; IBV, 48-64S [6, 8, 9]; TGEV, 60-70S [5]. 2.1.1.6 Molecular weight: HCV (229E), 5.8 × 106 [3]; HCV (OC43), 6.1 × 106 [4]; IBV, 5.6-9.0 × 106 [6, 7, 8, 9]. 2.1.1.11 Infectivity: IBV RNA is infectious [6, 8]. 2.1.1.12 Other features: HCV (229E) contains a covalently attached poly(A) tract of about 70 nucleotides at or near the 3′-terminus [3]. HCV (OC43) contains a covalently attached poly(A) tract of about 19 nucleotides [10]. IBV [6, 7, 8] and TGEV [11] also contain covalently attached poly(A) tracts. 2.1.2 Proteins 2.1.2.2 Number of polypeptides: HCV, 6 or 7 polypeptides [12, 13]; HEV, 5 polypeptides [14]; IBV, 7 polypeptides [15]; MHV, 4-6 polypeptides [16]; TGEV, 4-6 polypeptides [17]. 2.1.2.3 Molecular weights of polypeptides: HCV, 15,000-196,000 [12, 13]; HEV, 26,500-180,000 [14]; IBV, 33,000-130,000 [15]; MHV, 23,000-180,000 [16]; TGEV, 28,000-200,000 [17]. 2.1.2.5 Enzymes: RNA-dependent RNA polymerase not found in HCV (OC43) [10] or IBV [8]. There are unpublished reports that RNA- and DNA-dependent RNA polymerases are not found in HCV or IBV. 2.1.2.6 Other functional proteins: Hemagglutinin in HCV, IBV [18, 19], HEV and NCDCV [20]. Hemagglutinin inhibited by specific antisera. 2.1.3 Lipids: TGEV contains phospholipid and glycolipid resembling those of host cell [21]. 2 See 10.3 for abbreviations of species. 32.1.4 Carbohydrates: Several peptides are glycosylated, probably the surface peptides: HCV [12, 13]; HEV [14]; IBV [15]; MHV [22]; TGEV [17]. 2.2 Physicochemical properties 2.2.1 Density: 1.16-1.23 g/cm3 in sucrose; 1.23-1.24 g/cm3 in CsCl. 2.2.2 Sedimentation coefficient: HCV (229E), 378-400S; HCV (OC43), 374-416S; IBV, 330S; TGEV, 495S [23]. 2.2.4 Stability of infectivity 2.2.4.1 pH: IBV: optimum stability between pH 6.0 and 6.5. TGEV: optimum stability at pH 6.5. Conflicting or no evidence for other viruses. 2.2.4.2 Heat: Rapidly inactivated at 56°; slow inactivation at 37°; moderately stable at 4°, assuming optimal suspending medium. 2.2.4.5 Other agents: Unstable with common disinfectants and detergents. 2.3 Structure 2.3.1 Nucleocapsid: RNA associated with peptide of molecular weight 50,000: IBV [24]; MHV [22]; TGEV [23]. Helical RNP by negative staining [25, 25a]. 2.3.2 Envelope: Lipid-containing envelope present, including glycopeptides. See 2.1.4. 2.3.3 Cores: Electron-dense inner shell visible in thin section. HCV: ribonucleoprotein core, density 1.31 g/cm3 (CsCl), sedimentation coefficient 180S; linear appearance by negative staining. TGEV: ribonucleoprotein core, density 1.295 g/cm3 (CsSC4), sedimentation coefficient 650S [23]. 2.3.3.1 Dimensions: 50-70 nm in diameter in thin section. 2.4 Morphology 2.4.1 Overall shape: Flattened, dough-nut shape with some elongated forms. Spherical when freeze-dried. 2.4.2 Dimensions: 60-220 nm. 2.4.3 Surface projections: Characteristic bulbous projections, 12-24 nm long, widely spaced. 2.4.4 Special features in thin sections: Inner and outer shells, sometimes separated by electron-lucent space. 2.4.5 Other features: Fragile attachment of projections to surface of virion. Inner tongue-shaped membrane in IBV visible by negative staining [26]. 3 Replication 3.1 Site of accumulation of viral proteins: Cytoplasm. 43.3 Mode of nucleic acid replication 3.3.2 Effect of inhibitors: Sensitive to 6′-azauracil and virazole. Insensitive to 5′-iododeoxyuridine, 5′-bromodeoxyuridine, 5′-fluorodeoxyuridine, cytosine arabinoside, aminopterin and actinomycin D. 3.4 Site and mechanism of maturation: Matures in cytoplasm by budding through endoplasmic reticulum. 3.5 Other features: No budding at plasma membrane. 4 Cooperative interactions: No information available. 5 Host range 5.1 Natural: Generally restricted to normal host species. 5.2 Experimental 5.2.1 In vivo: Generally specific for species of origin. HCV (some strains): suckling hamsters, suckling mice. IBV (some strains): suckling hamsters, suckling white rats, newborn rabbits. MHV: hamsters. TGEV: cats, dogs, humans, muskrats, opossums, skunks, starlings. 5.2.2 In vitro: CCV: l°3 dog kidney cells. FIPV: None known. HCV (some strains; cf. serotype 229E): 1° and 2° human embryonic cells. Others: human embryo trachea organ cultures subsequently adapted to suckling mice and monkey kidney cells. HECV: organ culture of human intestine. HEV: 1° porcine cells. IBV: 1° chicken and chicken embryonic cells, chicken tracheal organ cultures, 1° monkey kidney cells, VERO cells. MHV: 1° mouse and mouse embryonic cells, mouse macrophages, L cells, WI-38 cells, NCTC-1496 cells. RCV and SDAV: 1° rat kidney cells. TGEV: 1° porcine cells (especially thyroid), 1° canine kidney cells, organ culture. 6 Pathogenicity 56.1 Association with diseases: CCV: Diarrhea in dogs [27]. CET: Diarrhea in turkeys. 3 1° = First passage. 6FIPV: Infectious peritonitis in cats [28]. HCV: Common colds in humans. HECV: Possibly diarrhea in humans [29]. HEV: Encephalitis in pigs. IBV: Acute respiratory disease, nephritis and gonadal damage in chickens. MHV: Acute hepatitis and/or encephalitis in mice, also chronic immunologically mediated diseases [30]. Also causative agent of LIVIM (lethal intestinal virus of infant mice) disease [31]. NCDCV: Gastroenteritis of calves. RCV: Pulmonary infections in rats. SDAV: Sialodacryoadenitis in rats. TGEV: Gastroenteritis in pigs. 6.2 Tissue tropisms: HCV: Upper respiratory tract, occasionally lower. HECV: Alimentary tract. HEV: Intestine, brain. IBV: Respiratory and reproductive tract. MHV: Brain, liver, spleen, macrophages. NCDCV: Small and large intestine. RCV: Lung. SDAV: Salivary glands. TGEV: Small intestine, lung. 6.3 Cytopathology: Cellular vacuolation leading to cell disintegration, sometimes syncytium formation. 7 Geographic distribution: Information limited and patchy. HCV, HECV, IBV, MHV and TGEV are certainly present in several continents and probably worldwide. 8 Transmission 78.1 Vertical: IBV, yes. No data available for other strains. 8.2 Horizontal: Yes. 8.3 Vectors 8.3.1 Biological: None recognized. 8.3.2 Mechanical: HCV, airborne; IBV, contaminated equipment, personnel, airborne, etc.; TGEV, fecal-oral route. No data for other strains. 9 Antigenic properties 9.1 Number of distinct antigenic molecules in virion: HCV, 3; HEV, 3; IBV, 3; MHV, 2; TGEV, 3. 89.2 Antigens involved in virus neutralization: (i) Viral surface glycopolypeptides. (ii) Anti-host antibody + complement. 9.3 Number of distinct nonstructural antigens: No adequate information. 9.4 Specificity of different antigens: No information. 10 Classification 10.1 Definition of family Coronaviridae: Pleomorphic enveloped particles, averaging 100 nm diameter, containing RNA and essential lipid. Bear unique definitive projections. Multiply in cytoplasm, mature by budding through endoplasmic reticulum. No defined subgroups, but a tentative grouping may be made on basis of serology though data are incomplete and somewhat contradictory. IBV has many recognized serotypes; however, all seem to be interrelated, possibly by a common antigen. No clear interrelationship demonstrated with any of the other coronaviruses, although may be related to TGEV. HCV, several serotypes, two main groups-those isolated in tissue culture and those isolated in organ culture. Serologically related to HEV, MHV and NCDCV. The three rodent coronaviruses-MHV, RCV and SDAV-are interrelated serologically and also related to HCV. No adequate information on relationship or diversity between individual strains of MHV. TGEV, no antigenic diversity between strains, possible relationship to FIPV and HEV. HEV, no antigenic diversity between strains, possible relationship to HCV, NCDCV and TGEV. CET, only one report available, no relationship shown to other coronaviruses. 10.2 Only one genus, Coronavirus. Type species: IBV. 10.3 Species: Avian infectious bronchitis virus (IBV) Canine coronavirus (CCV) Coronavirus enteritis of turkeys (CET) (bluecomb disease) Feline infectious peritonitis virus (FIPV) (feline coronavirus) Human coronavirus (HCV) Human enteric coronavirus (HECV) Murine hepatitis virus (MHV) Neonatal calf diarrhea coronavirus (NCDCV) Porcine transmissible gastroenteritis virus (TGEV) Porcine hemagglutinating encephalitis virus (HEV) Rat coronavirus (RCV) Sialodacryoadenitis virus of rats (SDAV)
  29 in total

1.  Haemagglutination by avian infectious bronchitis virus-a coronavirus.

Authors:  R W Bingham; M H Madge; D A Tyrrell
Journal:  J Gen Virol       Date:  1975-09       Impact factor: 3.891

2.  Intestinal infection of neonatal dogs with canine coronavirus 1-71: studies by virologic, histologic, histochemical, and immunofluorescent techniques.

Authors:  K P Keenan; H R Jervis; R H Marchwicki; L N Binn
Journal:  Am J Vet Res       Date:  1976-03       Impact factor: 1.156

3.  The ribonucleic acid of infectious bronchitis virus.

Authors:  H Watkins; P Reeve; D J Alexander
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

4.  Biological properties of avian coronavirus RNA.

Authors:  B Lomniczi
Journal:  J Gen Virol       Date:  1977-09       Impact factor: 3.891

5.  Presence of genomic polyadenylate and absence of detectable virion transcriptase in human coronavirus OC-43.

Authors:  G A Tannock; J C Hierholzer
Journal:  J Gen Virol       Date:  1978-04       Impact factor: 3.891

6.  Identification of heat-dissociable RNA complexes in two porcine coronaviruses.

Authors:  D J Garwes; D H Pocock; T M Wijaszka
Journal:  Nature       Date:  1975-10-09       Impact factor: 49.962

7.  The RNA of human coronavirus OC-43.

Authors:  G A Tannock
Journal:  Virology       Date:  1977-05-15       Impact factor: 3.616

8.  Coronaviridae.

Authors:  D A Tyrrell; J D Almeida; C H Cunningham; W R Dowdle; M S Hofstad; K McIntosh; M Tajima; L Y Zakstelskaya; B C Easterday; A Kapikian; R W Bingham
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

9.  Presence of infectious polyadenylated RNA in coronavirus avian bronchitis virus.

Authors:  G Schochetman; R H Stevens; R W Simpson
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

View more
  55 in total

1.  HPV or human parvovirus?

Authors:  C J Ronalds
Journal:  J Clin Pathol       Date:  1990-05       Impact factor: 3.411

Review 2.  Human viral gastroenteritis.

Authors:  G Cukor; N R Blacklow
Journal:  Microbiol Rev       Date:  1984-06

3.  In vivo morphogenesis of a new porcine enteric coronavirus, CV 777.

Authors:  R Ducatelle; W Coussement; M B Pensaert; P Debouck; J Hoorens
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

4.  Intracellular murine hepatitis virus-specific RNAs contain common sequences.

Authors:  S Cheley; R Anderson; M J Cupples; E C Chan; V L Morris
Journal:  Virology       Date:  1981-07-30       Impact factor: 3.616

5.  Significance of lysosomes in the morphogenesis of coronaviruses.

Authors:  R Ducatelle; J Hoorens
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

6.  Enzyme-linked immunosorbent assay for detection of antibody in volunteers experimentally infected with human coronavirus strain 229 E.

Authors:  C A Kraaijeveld; S E Reed; M R Macnaughton
Journal:  J Clin Microbiol       Date:  1980-10       Impact factor: 5.948

7.  Comparative analysis of RNA genomes of mouse hepatitis viruses.

Authors:  M M Lai; S A Stohlman
Journal:  J Virol       Date:  1981-05       Impact factor: 5.103

8.  Immunogenicity and antigenicity of human coronaviruses 229E and OC43.

Authors:  O W Schmidt; G E Kenny
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

9.  Bovine coronavirus structural proteins.

Authors:  B King; D A Brian
Journal:  J Virol       Date:  1982-05       Impact factor: 5.103

10.  Characterization of a coronavirus isolated from rats with sialoadenitis.

Authors:  M Maru; K Sato
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.